v3.24.2.u1
Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Research and development expenses        
Expenses incurred $ 249 $ 496 $ 624 $ 1,101
Less- government grants (155) (335)
Research and development expenses, net 94 496 289 1,101
Marketing expenses 28 162 196 334
General and administrative expenses 236 442 531 1,017
Total operating loss 358 1,100 1,016 2,452
Financial expenses, net 8 9 7 7
Loss for the period $ 366 $ 1,109 $ 1,023 $ 2,459
Basic loss per common stock $ (0.01) $ (0.02) $ (0.015) $ (0.04)
Dilutive loss per common stock $ (0.01) $ (0.02) $ (0.015) $ (0.04)
Weighted average number of ordinary shares - basic 70,281,511 69,029,424 70,106,284 68,919,197
Weighted average number of ordinary shares - diluted 70,281,511 69,029,424 70,106,284 68,919,197

Source